Recent Advances in Myelodysplastic Syndromes: Diagnosis, Prognosis and Clinical Therapy
A special issue of Cancers (ISSN 2072-6694). This special issue belongs to the section "Cancer Therapy".
Deadline for manuscript submissions: closed (1 November 2023) | Viewed by 8431
Special Issue Editor
Special Issue Information
Dear Colleagues,
Myelodysplastic syndromes (MDS) are a heterogenous group of clonal blood stem cell disorders, which mainly affect older patients and are characterized by hematopoietic insufficiency as well as an increased propensity for the development of secondary acute myeloid leukemia (sAML). While in early phases of the disease treatment approaches aim to improve ineffective hematopoiesis, the treatment goal in advanced phases is to prolong survival or even eradicate the disease by allogeneic stem cell transplantation (allo-SCT), with the latter representing the only curative option to date. For a long time, MDS have been considered to be hematopoietic-cell autonomous diseases originating from the accumulation of genetic and epigenetic alterations within the hematopoietic stem and progenitor cell (HSPC) population. Recently, it has become apparent that these myeloid disorders do not exclusively arise from HSPC but also involve the entire bone marrow microenvironment. Although understanding the complexity of the underlying mechanisms driving the disease still represents a challenge, elucidation of these processes begins to translate into our clinical day life. In this special issue we highlight recent advances in our understanding of the MDS pathophysiology and how this is integrated into novel diagnostic and therapeutic approaches.
Dr. Thomas Schroeder
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- myelodysplatics syndromes
- ineffective hematopoiesis
- mutations
- bone marrow microenvironment
- allogeneic stem cell transplantation
- diagnostic